Emmanuelle Tchernonog

1.3k total citations
17 papers, 282 citations indexed

About

Emmanuelle Tchernonog is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Emmanuelle Tchernonog has authored 17 papers receiving a total of 282 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 8 papers in Oncology and 7 papers in Genetics. Recurrent topics in Emmanuelle Tchernonog's work include Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Viral-associated cancers and disorders (5 papers). Emmanuelle Tchernonog is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Viral-associated cancers and disorders (5 papers). Emmanuelle Tchernonog collaborates with scholars based in France, United States and United Kingdom. Emmanuelle Tchernonog's co-authors include Guillaume Cartron, Steven Le Gouill, Camille Laurent, Paul Coppo, Charles Herbaux, Bettina Fabiani, Franck Morschhauser, Hervé Ghesquières, Olivier Casasnovas and Cédric Rossi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Molecular Sciences.

In The Last Decade

Emmanuelle Tchernonog

16 papers receiving 280 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emmanuelle Tchernonog France 7 214 203 90 43 38 17 282
Silvia Finotto Italy 10 127 0.6× 186 0.9× 166 1.8× 39 0.9× 14 0.4× 18 291
Leonard Jeffrey Medeiros United States 4 238 1.1× 186 0.9× 52 0.6× 15 0.3× 84 2.2× 5 296
Julie Crawford Australia 6 170 0.8× 87 0.4× 63 0.7× 41 1.0× 38 1.0× 11 263
Ana Batlle Spain 7 115 0.5× 151 0.7× 58 0.6× 28 0.7× 21 0.6× 15 248
Cornelis G. Scheepstra Netherlands 5 81 0.4× 192 0.9× 106 1.2× 66 1.5× 18 0.5× 6 272
Georges Delsol France 7 135 0.6× 162 0.8× 61 0.7× 70 1.6× 62 1.6× 9 332
Caoimhe Egan United States 6 88 0.4× 118 0.6× 45 0.5× 17 0.4× 61 1.6× 12 189
Alessandro Crotta United States 7 273 1.3× 121 0.6× 50 0.6× 55 1.3× 13 0.3× 26 369
L. Tedeschi Italy 8 168 0.8× 166 0.8× 45 0.5× 79 1.8× 36 0.9× 15 330
Lina Odqvist Sweden 6 150 0.7× 157 0.8× 44 0.5× 92 2.1× 23 0.6× 10 290

Countries citing papers authored by Emmanuelle Tchernonog

Since Specialization
Citations

This map shows the geographic impact of Emmanuelle Tchernonog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuelle Tchernonog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuelle Tchernonog more than expected).

Fields of papers citing papers by Emmanuelle Tchernonog

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuelle Tchernonog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuelle Tchernonog. The network helps show where Emmanuelle Tchernonog may publish in the future.

Co-authorship network of co-authors of Emmanuelle Tchernonog

This figure shows the co-authorship network connecting the top 25 collaborators of Emmanuelle Tchernonog. A scholar is included among the top collaborators of Emmanuelle Tchernonog based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emmanuelle Tchernonog. Emmanuelle Tchernonog is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Tchernonog, Emmanuelle, Aline Moignet, Amélie Anota, et al.. (2024). Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress. Haematologica. 109(8). 2401–2419. 3 indexed citations
3.
Tessoulin, Benoît, Franck Morschhauser, David Chiron, et al.. (2024). 5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial. Blood. 144(Supplement 1). 1657–1657. 1 indexed citations
4.
Ysebaert, Loïc, Emmanuelle Ferrant, Anne‐Sophie Michallet, et al.. (2023). Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group. Blood. 142(Supplement 1). 3273–3273. 1 indexed citations
5.
Gouill, Steven Le, Franck Morschhauser, David Chiron, et al.. (2023). P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.. HemaSphere. 7(S3). e6048802–e6048802. 1 indexed citations
6.
Hueso, Thomas, Thomas Gastinne, Catherine Thiéblemont, et al.. (2022). Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. Bone Marrow Transplantation. 57(4). 627–632. 3 indexed citations
7.
Duroux-Richard, Isabelle, Anne-Laure Gagez, Rémi Letestu, et al.. (2022). miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study. Frontiers in Immunology. 13. 983771–983771. 2 indexed citations
8.
Laethem, François Van, et al.. (2022). LAIR1, an ITIM-Containing Receptor Involved in Immune Disorders and in Hematological Neoplasms. International Journal of Molecular Sciences. 23(24). 16136–16136. 23 indexed citations
9.
Tudesq, Jean‐Jacques, Sylvain Lamure, Patrice Céballos, et al.. (2021). Coagulopathy Following Chimeric Antigen Receptor T Cell Therapy in R/R Adult B Cell Malignancies: A Single Center Experience. Blood. 138(Supplement 1). 4839–4839. 3 indexed citations
10.
Gouill, Steven Le, Franck Morschhauser, David Chiron, et al.. (2020). Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 137(7). 877–887. 75 indexed citations
11.
Lamure, Sylvain, Camille Carles, Philippe Quittet, et al.. (2019). Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma. JAMA Network Open. 2(4). e192093–e192093. 9 indexed citations
12.
Castillo, Jorge J., Francesco Baldini, Emmanuelle Tchernonog, et al.. (2019). Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. 3 indexed citations
13.
Gouill, Steven Le, Franck Morschhauser, Kamal Bouabdallah, et al.. (2019). Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients. Blood. 134(Supplement_1). 1530–1530. 6 indexed citations
14.
Tabaa, Yassine Al, Emmanuelle Tchernonog, Anne‐Ségolène Cottereau, et al.. (2018). Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 45(10). 1705–1709. 6 indexed citations
15.
Lamure, Sylvain, Camille Carles, Philippe Quittet, et al.. (2018). Occupational exposure to pesticides and prognosis of diffuse large B-cell lymphoma: A cohort study.. Journal of Clinical Oncology. 36(15_suppl). 1564–1564. 1 indexed citations
16.
Laurent, Camille, Bettina Fabiani, Catherine Do, et al.. (2016). Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. Haematologica. 101(8). 976–984. 67 indexed citations
17.
Tchernonog, Emmanuelle, Paul Coppo, Jehan Dupuis, et al.. (2016). Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Annals of Oncology. 28(4). 843–848. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Silvia Finotto Breakdown of academic impact, for papers by Leonard Jeffrey Medeiros Breakdown of academic impact, for papers by Julie Crawford Breakdown of academic impact, for papers by Ana Batlle Breakdown of academic impact, for papers by Cornelis G. Scheepstra Breakdown of academic impact, for papers by Georges Delsol Breakdown of academic impact, for papers by Caoimhe Egan Breakdown of academic impact, for papers by Alessandro Crotta Breakdown of academic impact, for papers by L. Tedeschi Breakdown of academic impact, for papers by Lina Odqvist
Rankless by CCL
2026